Webinar: Identifying the Best AAV Vectors for Safer, More Potent, and Reliable Therapeutic Performance.
In this GEN webinar, our distinguished guests, Dr. Arun Srivastava and Dr. David Schaffer will tell...
Newsroom
SIRION Biotech Opens a New Viral Vector Research and Manufacturing Center!
We are pleased to announce that we are expanding! Our new state-of-the-art laboratories will be...
Panel Discussion at BIO 2022 – Safety Aspects of AAV and Lentivirus-based Cell and Gene Therapy
SIRION Biotech is pleased to host the panel discussion on Safety Aspects of AAV and...
Meet us at the 2022 Sociedad Española de Terapia Génica y Celular (SETGYC) meeting in Seviila, from 30 May to 1 June!
Dr. Francois Vromman and Dr. Monserrat Vazquez-Rojas will be there to discuss your viral vector...
SIRION Biotech to present at ASGCT 25th Anniversary Meeting
Graefelfing, Germany – Viral technology specialist SIRION Biotech will be a high profile presence...
SIRION Receives ISO 9001:2015 Certification
Munich, Germany, February 23, 2022 – SIRION Biotech GmbH is proud to announce our achievement of...
PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
...
Subscribe Here!
Contact Us
Whether you seek help customizing a vector for academic use or support for your industrial R&D, we will assist you from square one to discuss and plan your project in detail.
News
SIRION Biotech licences its LentiBOOST® transduction technology to Cellectis
Meet us
AAV Webinar
On Demand
Swiss Biotech Day 2023
April 24-25, Basel
DG-GT Theme Day
27-28 April 2023, Langen